The optimal treatment for multidrug-resistant A. baumannii nosocomial infections has not
been established. Carbapenems are the mainstay of treatment in susceptible isolates …

Multidrug-resistant Acinetobacter baumannii is recognized to be among the most difficult
antimicrobial-resistant gram-negative bacilli to control and treat. Increasing antimicrobial …

The first decade of the 20th century witnessed a surge in the incidence of infections due to
several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter …

Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases
Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases Log in or …

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-
associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is …

Carbapenem-resistant Acinetobacter baumannii (CRAB) causes colonization and infection
predominantly in hospitalized patients. Distinction between the two is a challenge. When …

Amid the recent attention focused on the growing impact of methicillin-resistant
Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa infections, the …

Acinetobacter baumannii is a leading cause of healthcare-associated infections worldwide.
Because of various intrinsic and acquired mechanisms of resistance, most β-lactam agents …

Nosocomial infections caused by Acinetobacter baumannii have increased in recent years.
Isolates of multidrug-resistant A. baumannii (MDRAB) have been recovered in Taiwan since …

OBJECTIVE: To review and evaluate clinically relevant epidemiology, microbiology, and
clinical studies regarding the treatment of multidrug-resistant Acinetobacter infections. DATA …